Multicenter observational study on anticoagulation related bleeding events in emergency department patients

Sümeyye Çakmak; Özgür Söğüt; Buğra İlhan; Ruken Şimşekoğlu; Halil Doğan

Article Details

Multicenter observational study on anticoagulation related bleeding events in emergency department patients

Authors:

Sümeyye Çakmak | Özgür Söğüt | Buğra İlhan | Ruken Şimşekoğlu | Halil Doğan

Publisher:

Marmara University

Main Topics:

Pharmacology and Pharmaceutical Sciences (Other)

Journal:

Journal of Research in Pharmacy Vol.28 Issue 6, pp.2243-2250

Document Type:

Article

Publication Date:

6/2025

Document Language:

English

Document ID (Org No.):

2001334794

pISSN:

2630-6344

Keywords:

Abstract:

 We investigated bleeding complications in patients admitted to the emergency department ED who were taking oral anticoagulants and compared the rates of major and minor bleeding events between the direct oral anticoagulant DOAC and warfarin groups. We conducted a prospective, multicenter observational study of warfarinand DOAC-treated patients who presented to the EDs of tertiary-care hospitals between July 2020 and July 2021 with a bleeding event. Among 518 patients on anticoagulation therapy, 121 23.4 presented to EDs with bleeding events. A chart review revealed 73 60.24 patients with bleeding events who were taking a DOAC i.e., apixaban, edoxaban, rivaroxaban, or dabigatran and 48 who were taking warfarin. The rate of bleeding events was significantly higher among patients treated with warfarin than among those treated with DOACs 48129 37.2 vs. 73389 18.8, p0,001. Subgroup analysis of the DOAC-treated patients revealed a significant difference in the frequency of bleeding events among the DOAC groups p0.016, with a significantly lower frequency in patients treated with rivaroxaban versus edoxaban 14.9 vs. 34.7, p0.002 and in those treated with apixaban versus edoxaban 18.8 vs. 34.7, p0.021. Our findings indicate that although the rates of overall bleeding events differed among DOAC-treated patients, the rates of bleeding events were lower than those in warfarin-treated patients. Additionally, major bleeding events occurred less frequently in patients treated with rivaroxaban or apixaban compared with edoxaban.

 We investigated bleeding complications in patients admitted to the emergency department ED who were taking oral anticoagulants and compared the rates of major and minor bleeding events between the direct oral anticoagulant DOAC and warfarin groups. We conducted a prospective, multicenter observational study of warfarinand DOAC-treated patients who presented to the EDs of tertiary-care hospitals between July 2020 and July 2021 with a bleeding event. Among 518 patients on anticoagulation therapy, 121 23.4 presented to EDs with bleeding events. A chart review revealed 73 60.24 patients with bleeding events who were taking a DOAC i.e., apixaban, edoxaban, rivaroxaban, or dabigatran and 48 who were taking warfarin. The rate of bleeding events was significantly higher among patients treated with warfarin than among those treated with DOACs 48129 37.2 vs. 73389 18.8, p0,001. Subgroup analysis of the DOAC-treated patients revealed a significant difference in the frequency of bleeding events among the DOAC groups p0.016, with a significantly lower frequency in patients treated with rivaroxaban versus edoxaban 14.9 vs. 34.7, p0.002 and in those treated with apixaban versus edoxaban 18.8 vs. 34.7, p0.021. Our findings indicate that although the rates of overall bleeding events differed among DOAC-treated patients, the rates of bleeding events were lower than those in warfarin-treated patients. Additionally, major bleeding events occurred less frequently in patients treated with rivaroxaban or apixaban compared with edoxaban.

 We investigated bleeding complications in patients admitted to the emergency department ED who were taking oral anticoagulants and compared the rates of major and minor bleeding events between the direct oral anticoagulant DOAC and warfarin groups. We conducted a prospective, multicenter observational study of warfarinand DOAC-treated patients who presented to the EDs of tertiary-care hospitals between July 2020 and July 2021 with a bleeding event. Among 518 patients on anticoagulation therapy, 121 23.4 presented to EDs with bleeding events. A chart review revealed 73 60.24 patients with bleeding events who were taking a DOAC i.e., apixaban, edoxaban, rivaroxaban, or dabigatran and 48 who were taking warfarin. The rate of bleeding events was significantly higher among patients treated with warfarin than among those treated with DOACs 48129 37.2 vs. 73389 18.8, p0,001. Subgroup analysis of the DOAC-treated patients revealed a significant difference in the frequency of bleeding events among the DOAC groups p0.016, with a significantly lower frequency in patients treated with rivaroxaban versus edoxaban 14.9 vs. 34.7, p0.002 and in those treated with apixaban versus edoxaban 18.8 vs. 34.7, p0.021. Our findings indicate that although the rates of overall bleeding events differed among DOAC-treated patients, the rates of bleeding events were lower than those in warfarin-treated patients. Additionally, major bleeding events occurred less frequently in patients treated with rivaroxaban or apixaban compared with edoxaban.

 We investigated bleeding complications in patients admitted to the emergency department ED who were taking oral anticoagulants and compared the rates of major and minor bleeding events between the direct oral anticoagulant DOAC and warfarin groups. We conducted a prospective, multicenter observational study of warfarinand DOAC-treated patients who presented to the EDs of tertiary-care hospitals between July 2020 and July 2021 with a bleeding event. Among 518 patients on anticoagulation therapy, 121 23.4 presented to EDs with bleeding events. A chart review revealed 73 60.24 patients with bleeding events who were taking a DOAC i.e., apixaban, edoxaban, rivaroxaban, or dabigatran and 48 who were taking warfarin. The rate of bleeding events was significantly higher among patients treated with warfarin than among those treated with DOACs 48129 37.2 vs. 73389 18.8, p0,001. Subgroup analysis of the DOAC-treated patients revealed a significant difference in the frequency of bleeding events among the DOAC groups p0.016, with a significantly lower frequency in patients treated with rivaroxaban versus edoxaban 14.9 vs. 34.7, p0.002 and in those treated with apixaban versus edoxaban 18.8 vs. 34.7, p0.021. Our findings indicate that although the rates of overall bleeding events differed among DOAC-treated patients, the rates of bleeding events were lower than those in warfarin-treated patients. Additionally, major bleeding events occurred less frequently in patients treated with rivaroxaban or apixaban compared with edoxaban.

Article Details

Multicenter observational study on anticoagulation related bleeding events in emergency department patients

Authors:

Sümeyye Çakmak | Özgür Söğüt | Buğra İlhan | Ruken Şimşekoğlu | Halil Doğan

Publisher:

Marmara University

Main Topics:

Pharmacology and Pharmaceutical Sciences (Other)

Journal:

Journal of Research in Pharmacy Vol.28 Issue 6, pp.2243-2250

Document Type:

Article

Publication Date:

6/2025

Document Language:

English

Document ID (Org No.):

2001334794

pISSN:

2630-6344

Oral anticoagulants

bleeding events

direct oral anticoagulant

warfarin

Issues

Article Details

Multicenter observational study on anticoagulation related bleeding events in emergency department patients

Authors: Sümeyye Çakmak | Özgür Söğüt | Buğra İlhan | Ruken Şimşekoğlu | Halil Doğan

Publisher: Marmara University

Main Topics: Pharmacology and Pharmaceutical Sciences (Other)

Journal: Journal of Research in Pharmacy Vol.28 Issue 6, pp.2243-2250

Document Type: Article

Publication Date: 6/2025

Document Language: English

Document ID (Org No.): 2001334794

pISSN: 2630-6344

Oral anticoagulants

bleeding events

direct oral anticoagulant

warfarin

Issues

Authors:

Sümeyye Çakmak | Özgür Söğüt | Buğra İlhan | Ruken Şimşekoğlu | Halil Doğan

Publisher:

Marmara University

Main Topics:

Pharmacology and Pharmaceutical Sciences (Other)

Journal:

Journal of Research in Pharmacy Vol.28 Issue 6, pp.2243-2250

Document Type:

Article

Publication Date:

6/2025

Document Language:

English

Document ID (Org No.):

2001334794

pISSN:

2630-6344